Literature DB >> 17473225

Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy.

Dirk Westermann1, Sophie Van Linthout, Sameer Dhayat, Nasser Dhayat, Felicitas Escher, Carola Bücker-Gärtner, Frank Spillmann, Michel Noutsias, Alexander Riad, Heinz-Peter Schultheiss, Carsten Tschöpe.   

Abstract

OBJECTIVE: We investigated the effect of pharmacological inhibition of the interleukin converting enzyme (ICE) on cardiac inflammation, apoptosis, fibrosis, and left ventricular function in an animal model of diabetes. RESEARCH DESIGN AND METHODS: Diabetes was induced in 24 Sprague-Dawley rats by injection of streptozotozin (STZ) (70 mg/kg). Diabetic animals were treated with the interleukin converting enzyme (ICE) inhibitor (ICEI) (n = 12) or with a placebo (n = 12). Nondiabetic rats served as controls (n = 12). Left ventricular function was documented 6 weeks after induction of diabetes. Cardiac tissue was analyzed for the expression of cytokines, intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, leukocyte and macrophage integrins, and collagen. Phosphorylation of Akt was analyzed by Western blot and apoptosis by Blc-2 and Bax measurements.
RESULTS: Left ventricular function was significantly impaired in diabetic animals. This was accompanied by a significant increase of cytokines, cell adhesion molecules, leukocytes and macrophages, and collagen content. In addition, the phosphorylation state of Akt was reduced. These changes were significantly attenuated in the diabetic group treated with ICEI.
CONCLUSIONS: Cardiac dysfunction is associated with cardiac inflammation in experimental diabetic cardiomyopathy. Both of these--cardiac dysfunction and inflammation--are attenuated after treatment with ICEI. These data suggest that anticytokine-based therapies might be beneficial in diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473225     DOI: 10.2337/db06-1662

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  53 in total

1.  [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].

Authors:  Xian-Lang Ye; Wei-Chang Huang; Yan-Tao Zheng; Ying Liang; Wang-Qiu Gong; Chong-Miao Yang; Bin Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

Review 2.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

3.  Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression.

Authors:  Yuli Cai; Xiaorong Hu; Bo Yi; Ting Zhang; Zhongyuan Wen
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

4.  Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.

Authors:  Muhammad Ali; Azra Mehmood; Muhammad Sohail Anjum; Moazzam Nazir Tarrar; Shaheen N Khan; Sheikh Riazuddin
Journal:  Mol Cell Biochem       Date:  2015-09-10       Impact factor: 3.396

Review 5.  Diabetic cardiomyopathy: bench to bedside.

Authors:  Joel D Schilling; Douglas L Mann
Journal:  Heart Fail Clin       Date:  2012-08-09       Impact factor: 3.179

Review 6.  The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise.

Authors:  Joel D Schilling
Journal:  Antioxid Redox Signal       Date:  2015-04-15       Impact factor: 8.401

7.  Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart?

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas
Journal:  Ochsner J       Date:  2013

8.  Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes.

Authors:  Xiaoyu Wang; Susan V McLennan; Terri J Allen; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-02-02       Impact factor: 5.782

Review 9.  The complexities of diabetic cardiomyopathy: lessons from patients and animal models.

Authors:  Romain Harmancey; Heinrich Taegtmeyer
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

10.  Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy.

Authors:  Dirk Westermann; Thomas Walther; Konstantinos Savvatis; Felcicitas Escher; Meike Sobirey; Alexander Riad; Michael Bader; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.